Aspira Women's Health: 26% monthly volume growth, expanded Anthem & Medicaid, lower 2024 cash burn

Aspira Women's Health Inc.

OvaSuite product volume grew >26% in May 2024 vs January 2024; OvaWatch volume YTD up >88% vs 2023.
Anthem contracts expanded to CT, NH, ME, adding 2M lives; total 9M Anthem lives, expects 16M more.
Maryland and Kentucky added OvaWatch to Medicaid fee schedule at $897/test; nine states now cover OvaSuite.
Philippines OvaWatch commercial launch on track for Q3 2024; fee-per-test model expected to yield higher margins.
Company expects to lower 2024 cash used in operations guidance on Q2 2024 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.